SCHEMBL6490976

SCHEMBL6490976

O=C(CCCCOC1C(O)C(O)OC(CO)C1O)Oc1cccc(N2CCN(C(=O)c3c4ccccc4nc4ccccc34)CC2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.36
FAAH O00519 1/20 0.35
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
LMNA P02545 3/20 0.35
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
MGLL Q99685 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 3/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
MAPK1 P28482 2/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
P2RY12 Q9H244 1/20 0.34
HTR7 P34969 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480148 0.90 LGALS8 (0.40) KMT2AFAAHACACBACACALMNA
SCHEMBL6480127 0.87 KMT2A (0.36) KMT2AFAAHACACBACACALMNA
SCHEMBL6500007 0.80 ALDH1A1 (0.47) KMT2AFAAHACACBACACALMNA
SCHEMBL6489029 0.77 KMT2A (0.34) KMT2AACACBACACALMNAALDH1A1
SCHEMBL6491894 0.74 KMT2A (0.52) KMT2AFAAHACACBACACALMNA
SCHEMBL6479986 0.74 KMT2A (0.46) KMT2AACACBACACALMNAALDH1A1
SCHEMBL6480776 0.72 KMT2A (0.53) KMT2AFAAHACACBACACALMNA
SCHEMBL6481517 0.71 KMT2A (0.53) KMT2AFAAHACACBACACALMNA
SCHEMBL6480462 0.71 KMT2A (0.45) KMT2AFAAHACACBACACALMNA
SCHEMBL18854912 0.70 KMT2A (0.66) KMT2ALMNAALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors ZENTARIS GMBH (DE) 2005-01-13 US claimed
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors ZENTARIS GMBH (DE) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors PKD1, MDH2, MSH2 KMT2A 1945/4885FAAH 1108/4885ACACB 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.